TP53 and neoplasm: Kwok and collaborators demonstrated ALKBH5 is commonly deleted in AML, particularly in individuals with TP53 mutations, based on the cancer genome atlas (TCGA) data [97], implying ALKBH5’s tumor-suppressive function in AML.